Enabling up to 80 percent faster MRI scan times, the SubtleHD software is included in the newly launched AI software suite Subtle-Elite.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SubtleHD™, an artificial intelligence (AI) software that reportedly decreases magnetic resonance imaging (MRI) scan times by up to 80 percent for certain sequences.
The SubtleHD software also offers advanced denoising that one can apply for MRI assessment of any body region, according to Subtle Medical, the manufacturer of SubtleHD.
SubtleHD™, an artificial intelligence (AI) software that reportedly enables significant reduction in magnetic resonance imaging (MRI) scan times, has garnered 510(k) clearance from the Food and Drug Administration (FDA). (Images courtesy of Subtle Medical.)
The company is including SubtleHD in a new Subtle-Elite AI software suite that also includes the previously FDA-cleared SubtleSynth, which utilizes deep learning to provide synthetic short tau inversion recovery (STIR) images from T1 and T2-weighted MRI, and SubtleAlign, which provides optimal anatomical alignment for brain MRI scans.
"The FDA clearance of Subtle-HD™ marks a significant milestone in AI-driven radiology, giving hospitals and imaging centers a powerful solution to increase efficiency, improve image quality, and optimize workflows — all without additional hardware costs," noted Ajit Shankaranarayanan, Ph.D., the chief product officer at Subtle Medical. "By combining SubtleHD, SubtleSYNTH, and SubtleALIGN into a single, comprehensive package, Subtle-ELITE™ is setting a new benchmark for the future of MRI."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.